DGX vs OPK
DGX: A leading national provider of diagnostic testing and medical insights, delivering clinical laboratory services through an extensive network of patient centers and hospitals. OPK: OPKO Health combines specialty pharmaceuticals (long-acting growth hormone and hyperparathyroidism treatments) with clinical diagnostics and laboratory testing, but faces steep revenue headwinds and persistent losses.
Side-by-side fundamentals
| Metric | DGX | OPK | Edge |
|---|---|---|---|
| Price as of 2026-07-23 close | $227.90 | $1.17 | |
| Market cap as of 2026-07-24 | $24.9B | $895M | |
| P/E as of 2026-07-24 | 24.34 | n/a | |
| PEG as of 2026-07-24 | 2.41 | -0.02 | OPK lower |
| Net margin as of 2026-07-24 | +9.1% | -36.5% | DGX higher |
| Gross margin as of 2026-07-24 | +33.3% | +38.0% | OPK higher |
| Operating margin as of 2026-07-24 | +14.3% | -33.2% | DGX higher |
| ROE as of 2026-07-24 | +14.1% | -16.7% | DGX higher |
| ROA as of 2026-07-24 | +6.3% | -10.9% | DGX higher |
| Debt / equity as of 2026-07-24 | 0.77 | 0.29 | OPK lower |
| Revenue growth (YoY) as of 2026-07-24 | +11.0% | -29.0% | DGX higher |
| Revenue CAGR (3y) SEC XBRL | +3.7% | -15.5% | DGX higher |
| Dividend yield as of 2026-07-24 | +1.6% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-24 | 0.54 | 1.50 | |
| 1-year return as of 2026-07-23 close | +33.7% | -18.2% | DGX higher |
Fundamentals: Finnhub, as of 2026-07-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-23.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.